Skip to main content
. 2019 Oct 5;11:1759720X19877994. doi: 10.1177/1759720X19877994

Figure 1.

Figure 1.

Behavior of biochemical markers of bone formation (serum P1NP) and resorption (serum bCTX) following treatment with teriparatide, abaloparatide, and romosozumab.

Redrawn with permission from Minisola et al.18

bCTX, carboxy-terminal cross-linking telopeptide of type I collagen; P1NP, procollagen type I N-terminal propeptide.